Exclusive: RA Capital backs intranasal viral prophylactic with $34M and a plan for Phase 2b
RA Capital led a $34M round into Northlinks Bio, an intranasal viral prophylactic company, with plans to launch a Phase 2b trial.
Northlinks Bio
Private
Profile of Northlinks Bio created from news harvest. To be enriched by user.
Company Info
Sector:Infectious disease / Intranasal prophylaxis
Headquarters:United States
Founded:2024
Website:www.northlinksbio.com/
Clinical Development Pipeline
Undisclosed
Target: TBDRecent News
Leadership Team
Fanny Cavalié
Chief Executive Officer
Careers & Job Openings
No active job listings. Check back later.